|
|
|
|
|
|
BIOSKETCH Dr. Slain, Pharm.D is currently an Associate Professor at West Virginia University. He received his Pharmacy degree and his Doctor of Pharmacy (Pharm.D.) degree from Duquesne University in Pittsburgh. He then completed a residency and fellowship in infectious diseases pharmacotherapy at the Medical College of Virginia in Richmond. Additionally, he has the distinction of being a Board Certified Pharmacotherapy Specialist (BCPS). Dr. Slain is an anti-infective clinical specialist on the WVU Infectious Diseases Consult Service and in the outpatient Infectious Diseases Clinic. In addition, he teaches in several courses in the schools of Pharmacy, Medicine, and Graduate Nursing. He has received multiple teaching awards for his novel teaching approaches in the School of Pharmacy. Dr. Slain is active at the national level in several infectious diseases and pharmacy associations. Dr. Slain was selected as "Clinician of the Year" by The Society of Infectious Diseases Pharmacists (SIDP). He is WVU’s faculty liaison to two national associations that serve the needs of clinical pharmacy practitioners (The American Society of Health-System Pharmacist (ASHP) and The American College of Clinical Pharmacy (ACCP). He is the program director and principal mentor for the Infectious Diseases Pharmacotherapy Specialized Residency. Dr. Slain’s research has been published in respected peer-reviewed journals. Dr. Slain speaks frequently at regional and national meetings and conferences. In addition, he serves as a consultant to the Pharmaceutical industry and to other health care institutions. EDUCATION Infectious Diseases Residency & Fellowship, Virginia Commonwealth University- TEACHING INTERESTS AND COURSES TAUGHT Courses taught: PHAR 730 Pathophysiology and Therapeutics III, Infectious DiseasesModule Coordinator and Instructor PRACTICE INTERESTS Dr. Slain’s clinical practice sites at WVU include the Infectious Diseases Consult Service and the outpatient Infectious Diseases clinic. He is a member of WVU Hospitals Antibiotic Committee of the Pharmacy and Therapeutics Committee. He is a key member in the institution’s antibiotic stewardship program RESEARCH AND SCHOLARSHIP INTERESTS Antifungal therapies SELECTED PUBLICATIONS Research Articles Slain D, Amsden J.R., Khakoo R.A., Fisher M.A., Lalka D., Hobbs G.R. Effect of High-Dose Vitamin C on the Steady-State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers. Pharmacotherapy 2005;25:165-70. Slain D, Abate M, Hodges BM, Stamatakis MK, Wolak S. Evaluation of an interactive response system to promote active learning and skills development in the doctor of pharmacy curriculum. Am J Pharm Educ 2004;68(5):Article 117. Stamatakis MK, Schreiber JM, Slain D, Gunel E. Vancomycin administration during dialysis with low-flux polysulfone membranes: Traditional versus a supplemental dosage regimen. Am J Health-Sys Pharm 2003;60:1564-8. Slain D, Miller K, Khakoo RA, Fisher MA, Wierman T, Jozefczyk K. Infrequent Occurrence of Amphotericin B Lipid Complex (ABLC)-Associated Nephrotoxicity in Various Clinical Settings at a University Hospital. Clinical Therapeutics 2002; 24:1636-42. Slain D, Casdorph D, McIntire T. Assessment Of An Antiretroviral Adherence Sensitivity Training Exercise In The Doctor Of Pharmacy Curriculum. Am J Pharm Educ 2002: 66: 277-80. Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg S, Lou Y, Moore KHP, Wooley J, Stein DS. Metabolic disposition and pharmacokinetics of [14C]-Amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered in a single, oral dose to healthy male subjects. J Clin Pharmacol 2001; 41: 386-96. Slain D, Pakyz A, Israel D, Monroe SG, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000;20:898-907. Review Articles Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: A focus on current and future antifungal treatment options. Pharmacotherapy 2007; 27: 1711-21. Slain D, Rogers RD, Chapman S, Cleary J. Intravenous hydroxypropyl-b-cyclodextrin formulation of itraconazole: Formulary focus. Ann Pharmacother 2001; 35: 720-9. Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999;19 (3):306-23. Book Chapters Slain D. Invasive fungal infections. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 7th Edition. McGraw-Hill, New York, 2007. Bergman S, Slain D. Dermatophytosis. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 7th Edition. McGraw-Hill, New York, 2007. Slain D. Infections in immunocompromised patients: A patient-focused approach. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 7th Edition. McGraw-Hill, New York, 2007. Slain D. Antifungal Agents: Clinical Significance section (chapter 40), In: Williams DA, Lemke TL, Eds. Foye’s Principles of Medicinal Chemistry, 6th Edition. Lippincott Williams & Wilkins, Philadelphia, 2007. Slain D. Antiviral Agents and Protease Inhibitors: Clinical Significance section (chapter 43), In: Williams DA, Lemke TL, Eds. Foye’s Principles of Medicinal Chemistry, 6th Edition. Lippincott Williams & Wilkins, Philadelphia, 2007. Slain D. Pneumonia [Chapter 75]. In: Helms RA, Quan DJ, Eds. Textbook of Therapeutics: Drug and Disease Management, 8th edition. Lippincott Williams & Wilkins, Philadelphia, 2006. Hodges B, Slain D. Ventilator-Associated Pneumonia [Case 30]. In: Helms RA, Quan DJ, Eds. Textbook of Therapeutics: Drug and Disease Management, 8th edition. Lippincott Williams & Wilkins, Philadelphia, 2006. Slain D. Infections in immunocompromised patients (Chapter 132): A patient-focused approach. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 6th Edition. McGraw-Hill, New York, 2005. SELECTED PRESENTATIONS An Update on HIV Therapeutics for Pharmacists. Virginia Society of Health-System Pharmacists (VSHP) Annual Meeting, April 14-15, 2007, Wintergreen Resort, VA. Treatment Of Fungal Pathogens In The Immunocompromised Patient. 16th Annual Conference of the National Home Infusion Association. Savannah, GA. February 26- March 1, 2007 Drugs vs. Bugs: A Concise Review of Key Issues in Anti-Infective Therapeutics. 41st Annual American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Anaheim, CA. December 9, 2006. Empiric Therapy Decisions for Serious Infections: A Consideration of Appropriate Therapy. Pharmacotherapy Grand Rounds. University of Tennessee, Memphis, TN November 16, 2006 Antimicrobials and Resistance. 2006 OVMC Infectious Diseases Symposium. Ohio Valley Medical Center, Wheeling, WV. October 7, 2006. Safeguards for Serious Infections: A Consideration of Appropriate Empiric Antibiotic Therapy. Virginia Society of Health-System Pharmacists Meeting, Region IV. Richmond, VA. October 27, 2005. A Seasoned Look at Newer Antifungals: Truly Advantageous or is Redundazole Here? Annual Meeting of the American College of Clinical Pharmacy. San Francisco, October 23-26, 2005 New Anti-Infectives and the Treatment of Resistant Organisms. 14th Annual Meeting of the National Home Infusion Association. New Orleans, LA. February 13, 2005. Clinical Management of Fungal Infections. 14th Annual Meeting of the National Home Infusion Association. New Orleans, LA. February 13, 2005. Linezolid vs.Vancomycin for the Treatment of Nosocomial or Ventilator-Associated Pneumonia. Significant Paper Session. Annual Meeting of the American College of Clinical Pharmacy. Dallas, TX. October 24-27, 2004.New Antifungal Formulations. 38th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting. New Orleans, LA. December 9, 2003.
|
||||
